Debbie doesn't know that Cipramil is now indicated for disorder ... she just knows her doctor made a logical choice
As a patient with Panic Disorder, Debbie is beginning to appreciate the value of the Cipramil treatment that her doctor has newly prescribed.
Of course, Debbie would no more talk of the recently extended indication for Cipramil than its high selectivity12, good tolerability3, and low risk of drug interactions06. She just recognises the difference that Cipramil makes to the stability and quality of her life.
Presentation: 'Cipramil' tablets 10 mg: PL 0*58/0057, each containing 10 mg of citalopram as the hydrobromide. 28 (OP) 10 mg tablets Â£12.77. 'Cipramil' tablets 20 mg: PL 0458/0058, each containing 20 mg of otalopram as the hydrobromide.
28 (OP) 20 mg tablets Â£21.26. Indications: Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence.
Treatment of panic disorder, with or without agoraphobia. Dosage: Treating depression: Adults: 20 mg a day. Depending upon individual patient response, this may be increased in 20 mg incre ments to a maximum of 60 mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. Treatment fot at least 6 months is usually necessary to provide adequate maintenance against the potential for relapse. Treating panic disorder: 10 mg daily for the first week, increasing to 20 mg daily. Depending upon individual patient response, dosage may be further increased to a maximum of 60 mg daily. Depending upon individual patient response, it may be necessary to continue treatment for several months. Elderly: 20 mg a day increasing to a maximum of 40 mq dependent upon individual patient response. The British Journal of Psychiatry is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The BJPpublishes original work in all fields of psychiatry. Manuscripts for publication should be sent to the Editor, British journal of Psychiatry. 17 Belgrave Square. London SWIX 8PG. Queries, letters to the Editor and book reviews may also be sent electronically to zashmore@rcpsych.ac.uk.
Instructions to authors
Full instructions to authors are given at the beginning of the January and July issues, and on the Web Site below. Thi. e One
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Editor Adelaide offers arguably the best lifestyle in Australia. Fringed by the ocean and surrounded by greens hills, decked with vineyards, the city is the jewel in the crown of South Australia. Known for its "laid back" attitude and commitment to the arts, this spacious city has a cosmopolitan feel complimented by easy access to dramatic and beautiful countryside.
Our client is part of a healthcare network based in Adelaide with a commitment to the pursuit of excellence in clinical care, teaching and research. Covering two major teaching hospitals totalling 600 beds and affiliated with the University of Adelaide Medical School, the service provides a broad range of community and hospital based psychiatric services to a population of 500,000.
Due to expansion of the service a new opportunity now exists for a consultant psychiatrist who is registrable with the Medical Board of South Australia. Overseas applicants with suitable post-graduate qualifications (equivalent to RANZCP) will be well received and assistance will be offered with relocation.
You have at least three years experience as a specialist and your commitment to teaching and research activities will help you fulfil this diverse role. Your adventurous spirit will help you settle into the Australian way of life and you will find yourself warmly welcomed. . Presentations 25mg and 100 mg clozapine tablets. Dosage and Administration Initiation must be in hospital inpatients and is restricted to patients with normal white blood cell and differential counts. Initially, 12.5 mg once or twice on the first day, followed by one or two 25 mg tablets on the second day. Increase dose slowly, by increments to reach a therapeutic dose within the range of 200 -450mg daily (see data sheet). The total daily dose should be divided and a larger portion of the dose may be given at night. Once control is achieved a maintenance dose of 150 to 300 mg daily may suffice. At daily doses not exceeding 200mg, a single administration in the evening may be appropriate. Exceptionally, doses up to 900 mg daily may be used. Patients with a history of epilepsy should be closely monitored during CLOZARIL therapy since dose-related convulsions have been reported. Patients with a history of seizures, as well as those suffering from cardiovascular, renal or hepatic disorders, together with the elderly need lower doses (12.5 mg given once on the first day) and more gradual titration. Contra-Indications Allergy to any constituents of the formulation. History of druginduced neutropenia/agranulocytosis, myeloproliferative disorders, uncontrolled epilepsy, alcoholic and toxic psychoses, drug intoxication, comatose conditions, circulatory collapse and/or CNS depression of any cause, severe renal or cardiac failure, active liver disease, progressive liver disease or hepatic failure. Warning CLOZARIL can cause agranulocytosis. A fatality rate of up to 1 in 300 has been estimated when CLOZARIL was used prior to recognition of this risk. Since that time strict haematological monitoring of patients has been demonstrated to be effective in markedly reducing the risk of fatality. Therefore, because of this risk its use is limited to treatment-resistant schizophrenic patients:-1. who have normal leucocyte findings and 2. in whom regular leucocyte counts can be performed weekly during the first 18 weeks and at least every two weeks thereafter for the first year of therapy. After one year's treatment, monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after complete discontinuation of CLOZARIL. Patients must be under specialist supervision and CLOZARIL supply is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. Prescribing physicians must register themselves, their patients and a nominated pharmacist with the CLOZARIL Patient Monitoring Service. This service provides for the required leucocyte counts as well as a drug supply audit so that CLOZARIL treatment is promptly withdrawn from any patient who develops abnormal leucocyte findings. Each time CLOZARIL is prescribed, patients should be reminded to contact the treating physician immediately if any kind of infection begins to develop, especially any flu-like symptoms. Precautions CLOZARIL can cause agranulocytosis. Perform pre treatment white blood cell count and differential count to ensure only patients with normal findings receive CLOZARIL. Monitor white blood cell count weekly for the first 18 weeks and at least two-weekly for the first year of therapy. After one year's treatment, monitoring may change to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after complete discontinuation.
If signs or symptoms of infection develop an immediate differential count is necessary. If the white blood count falls below 3.0 x lOVL and/or the absolute neutrophil count drops below 1.5 x 1(P/U withdraw CLOZARIL immediately and monitor the patient closely, paying particular attention to symptoms suggestive of infection. Re-evaluate any patient developing an infection, or when a routine white blood count is between 3.0 and 3.5 x 10VL and/or a neutrophil count between 1.5 and 2.0 x 10VL, with a view to discontinuing CLOZARIL Any further fall in white blood/neutrophil count below 1.0 x lOVL and/or 0.5 x 109/L respectively, after drug withdrawal requires immediate specialised care, where protective isolation and administration of GM-CSF or G-CSF and broad spectrum antibiotics may be indicated. Colony stimulating factor therapy should be discontinued when the neutrophil count returns above 1.0 x lO^/L. CLOZARIL lowers the seizure threshold. Orthostatic hypotension can occur therefore close medical supervision is required during initial dose titration. Patients affected by the sedative action of CLOZARIL should not drive or operate machinery, administer with caution to patients who participate in activities requiring complete mental alertness. Monitor hepatic function regularly in liver disease. Investigate any signs of liver disease immediately with a view to drug discontinuation. Resume only if LFTs return to normal, then closely monitor patient. Use with care in prostatic enlargement, narrow-angle glaucoma and paralytic ileus. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. Avoid immobilisation of patients due to increased risk of thromboembolism. Do not give CLOZARIL with other drugs with substantial potential to depress bone marrow function. CLOZARIL may enhance the effects of alcohol, MAO inhibitors, CNS depressants and drugs with anticholinergic, hypotensive or respiratory depressant effects. Caution is advised when CLOZARIL therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic drug as these patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest. Caution is advised with concomitant administration of therapeutic agents which are highly bound to plasma proteins. Clozapine binds to and is partially metabolised by the isoenzymes cytochrome P450 1A2 and P450 2D6. Caution is advised with drugs which posses affinity for these isoenzymes. Concomitant cimetidine and high dose CLOZARIL was associated with increased plasma clozapine levels and the occurrence of adverse effects. Concomitant fluoxetine and fluvoxamine have been associated with elevated clozapine levels. Discontinuation of concomitant carbamazepine resulted in increased clozapine levels. For all those depressed patients who need a helping hand to face life again, make 'Seroxat' your first-choice prescription for depression.
/ PAROXETINE
Rebuilding the lives of anxious depressed patients 
General Adult Psychiatry
Edited by George Stein & Greg Wilkinson
A major new textbook of adult general psychiatry by leading experts in the field and the centrepiece of the Seminars series. This multi-authored textbook places its greatest emphasis on detailed clinical descriptions of the common psychiatric disorders and their place within the ICD-10 and DSM-IV schemes. Psychological and biological treatments are covered in depth giving the reader an insight into the issues involved in modern patient care. Although primarily intended for doctors preparing for their MRCPsych, the text provides a comprehensive well-referenced review of the whole of modern clinical psychiatry and will be of use to consultant psychiatrists and other health professionals in the mental health field. As with other titles in the series, frequent use of boxes, tables and figures is made to set out important points and key information. The book is presented in two volumes as a boxed set. 
